Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 231-617-5 | CAS number: 7652-64-4
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Acute Toxicity: oral
Administrative data
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 1994
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 994
- Report date:
- 1994
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 401 (Acute Oral Toxicity)
- Version / remarks:
- 1981
- Deviations:
- no
- GLP compliance:
- no
- Remarks:
- The study was conducted prior to the creation of the REACH regulation. The study was well documented and is sufficient for classification.
- Test type:
- standard acute method
- Limit test:
- no
Test material
- Reference substance name:
- 1,1'-(1,3-phenylenedicarbonyl)bis[2-methylaziridine]
- EC Number:
- 231-617-5
- EC Name:
- 1,1'-(1,3-phenylenedicarbonyl)bis[2-methylaziridine]
- Cas Number:
- 7652-64-4
- Molecular formula:
- C14H16N2O2
- IUPAC Name:
- 2-methyl-1-[3-(2-methylaziridine-1-carbonyl)benzoyl]aziridine
Constituent 1
- Specific details on test material used for the study:
- STABILITY AND STORAGE CONDITIONS OF TEST MATERIAL
- Storage condition of test material: The test material was stored frozen.
FORM AS APPLIED IN THE TEST (if different from that of starting material): The test material was thawed and administered undiluted
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Laboratories, Inc. Portage, MI
- Weight at study initiation: approximately 264 g (males) and 243 g (females)
- Fasting period before study: Fasted overnight prior to test material administration
- Housing: Housed in group cages (by sex) in temperature and humidity controlled quarters
- Diet (e.g. ad libitum): ad libitum; Laboratory Rodent Diet #5001, Purina Mills, Inc
- Water (e.g. ad libitum): ad libitum
- Acclimation period: At least 7 days
IN-LIFE DATES: From: 25 February 1994 To: 22 April 1994
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- unchanged (no vehicle)
- Details on oral exposure:
- The undiluted test material was brought to room temperature and administered by gavage using a bulk density determination of 1.11 g/mL to determine the dose volume for each dose level. An individual dose was calculated for each animal based on its fasted body weight.
- Doses:
- 500 and 5000 mg/kg bw
- No. of animals per sex per dose:
- 5/sex/dose
- Control animals:
- no
- Details on study design:
- - Duration of observation period following administration: 14 days
- Frequency of observations and weighing: Clinical obervations and mortality checks at 1, 2.5, and 4 hours after test material administration. Additional clinical observations and twice daily mortality checks (morning and afternoon) were conducted daily thereafter for 14 days. Body weights were determined before test material administration (Day 0), at Day 7, and at termination of the experimental phase (Day 14).
- Necropsy of survivors performed: yes - Statistics:
- No statistical analyses were required by the protocol.
Results and discussion
Effect levels
- Key result
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- > 500 - < 5 000 mg/kg bw
- Based on:
- test mat.
- Mortality:
- All mortality occurred within 5 days of administration of the test material; 2 of 5 female (day 1 and 5) and none of 5 males died at the 500 mg dose while 5 of 5 females and 5 of 5 males died at the 5 g dose between 2.5 hours and 1 day after administration of the test material.
- Clinical signs:
- other: Clinical signs of toxicity included excessive salivation, red-stained face, miosis, thin appearance, hypoactivity, lacrimation, soft stool, yellow-stained urogenital area, staggered gait, squinting eyes, dyspnea, absence of rightly/grasping reflex, gaspin
- Gross pathology:
- There were no visible lesions in any of the animals.
Applicant's summary and conclusion
- Interpretation of results:
- Category 4 based on GHS criteria
- Conclusions:
- Based on the results of the study, the test article has a rat oral LD50 between 500 and 5000 mg/kg body weight.
- Executive summary:
Two groups of ten albino rats (Sprague-Dawley strain, five males, five females) weighing between 228 and 273 grams received an oral dose of the test article equivalent to either 500 mg (0.45 mL) or to 5000 mg (4.50 mL) per kilogram of body weight. This study was conducted according to OECD 401 (1981). Clinical signs of toxicity included excessive salivation, red-stained face, miosis, thin appearance, hypoactivity, lacrimation, soft stool, yellow-stained urogenital area, staggered gait, squinting eyes, dyspnea, absence of rightly/grasping reflex, gasping and death. All mortality occurred within 5 days of administration of the test material; 2 of 5 female and none of 5 males died at the 500 mg dose while 5 of 5 females and 5 of 5 males died at the 5 g dose between 2.5 hours and 1 day after administration of the test material. All surviving animals returned to a normal appearance by day 6 after treatment. There was no meaningful effect on body weight gain in surviving animals. The gross necropsy at termination revealed no visible lesions in any test animals. Based on the results of the study, the test article has a rat oral LD50 between 500 and 5000 mg/kg body weight.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.